Schmieder et al.: Additional Antiproteinuric Effect of UltrahighDose Candesartan: A Double-Blind, Randomized, Prospective Study.J Am Soc Nephrol 16: 3038–3045, 2005.
The authors regretfully report an error in quoting the findingsof the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria2 (IRMA 2) Study at the bottom of the left column on page 3043.The second sentence of the paragraph beginning, "Various clinicalstudies support... ," should read as follows:
The largest trial in patients with type 2 diabetes and microalbuminuria,the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria2 (IRMA 2) Study, found that progression of diabetic nephropathyoccurred in approximately 5% of patients who had diabetes andreceived a high dose of ARB (irbesartan 300 mg/day): In 10%of those who received a low dose of ARB (irbesartan 150 mg/day)and in 15% of the control group who received placebo on topof other antihypertensive medication (32).
Wahab et al.: Connective Tissue Growth Factor CCN2 Interactswith and Activates the Tyrosine Kinase Receptor TrkA. J Am SocNephrol 16: 340–351, 2005.
In this article, Figure 5 is in fact a duplicate of Figure 12.Please see the correct Figure 5 below. The legend for Figure5 is correct as published. The publisher regrets this error.
Also in this article, the authors would like to correct a referenceto Figure 13. On page 347, in the second line from the top ofthe right column, the textual reference to Figure 11 shouldrefer instead to Figure 13. The authors regret this error.
Top
Correction
